Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CYTK Cytokinetics	$38.68 +1.8%	$32.96	$29.31 ▼ $61.38	$4.54B	0.59	1.53 million shs	1.63 million shs
KRYS Krystal Biotech	$150.08 +1.6%	$136.02	$122.80 ▼ $219.34	$4.27B	0.67	286,159 shs	280,630 shs
PAHC Phibro Animal Health	$30.54 -0.1%	$25.48	$16.16 ▼ $31.80	$1.24B	0.75	221,767 shs	262,604 shs
RYTM Rhythm Pharmaceuticals	$91.44 +2.3%	$65.90	$40.61 ▼ $94.80	$5.69B	2.26	586,227 shs	727,203 shs

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CYTK Cytokinetics	+1.76%	+5.60%	+14.51%	-2.03%	-31.85%
KRYS Krystal Biotech	+1.59%	+0.79%	+12.81%	-10.97%	-28.04%
PAHC Phibro Animal Health	-0.07%	-2.71%	+23.59%	+76.63%	+60.31%
RYTM Rhythm Pharmaceuticals	+2.33%	+2.74%	+46.56%	+48.10%	+69.68%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CYTK Cytokinetics	4.0402 of 5 stars	4.5	1.0	0.0	4.6	2.2	0.8	0.0
KRYS Krystal Biotech	4.5569 of 5 stars	3.5	1.0	0.0	4.7	2.2	3.3	1.9
PAHC Phibro Animal Health	4.0323 of 5 stars	0.9	4.0	2.5	1.1	3.3	3.3	2.5
RYTM Rhythm Pharmaceuticals	3.1648 of 5 stars	2.5	1.0	0.0	4.3	2.6	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CYTK Cytokinetics	2.93	Moderate Buy	$70.92	83.36% Upside
KRYS Krystal Biotech	3.00	Buy	$213.75	42.42% Upside
PAHC Phibro Animal Health	1.83	Reduce	$24.40	-20.10% Downside
RYTM Rhythm Pharmaceuticals	3.07	Buy	$91.00	-0.48% Downside

Current Analyst Ratings Breakdown

Latest PAHC, KRYS, RYTM, and CYTK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/10/2025	RYTM Rhythm Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
7/10/2025	RYTM Rhythm Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Outperform	$76.00 ➝ $110.00
7/10/2025	RYTM Rhythm Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$73.00 ➝ $95.00
7/10/2025	RYTM Rhythm Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$91.00 ➝ $129.00
7/10/2025	RYTM Rhythm Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$97.00
7/9/2025	KRYS Krystal Biotech	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$155.00 ➝ $176.00
7/9/2025	RYTM Rhythm Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Overweight ➝ Overweight	$95.00
7/9/2025	RYTM Rhythm Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$72.00 ➝ $95.00
7/7/2025	PAHC Phibro Animal Health	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$25.00 ➝ $35.00
7/7/2025	RYTM Rhythm Pharmaceuticals	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/7/2025	RYTM Rhythm Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform ➝ Outperform	$88.00

(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CYTK Cytokinetics	$18.47M	250.11	N/A	N/A	($1.15) per share	-33.63
KRYS Krystal Biotech	$290.52M	14.93	$4.71 per share	31.86	$32.90 per share	4.56
PAHC Phibro Animal Health	$1.02B	1.22	$2.11 per share	14.46	$6.34 per share	4.82
RYTM Rhythm Pharmaceuticals	$130.13M	44.70	N/A	N/A	$0.35 per share	261.26

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CYTK Cytokinetics	-$589.53M	-$5.29	N/A	N/A	N/A	-3,201.47%	N/A	-43.75%	8/6/2025 (Estimated)
KRYS Krystal Biotech	$89.16M	$4.16	36.08	14.89	N/A	37.17%	14.64%	13.28%	8/4/2025 (Estimated)
PAHC Phibro Animal Health	$2.42M	$0.78	39.15	14.54	0.51	2.68%	30.51%	6.89%	8/27/2025 (Estimated)
RYTM Rhythm Pharmaceuticals	-$260.60M	-$2.81	N/A	N/A	N/A	-123.26%	-739.62%	-44.27%	8/5/2025 (Estimated)

Latest PAHC, KRYS, RYTM, and CYTK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	N/A	CYTK Cytokinetics	-$1.32	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	RYTM Rhythm Pharmaceuticals	-$0.64	N/A	N/A	N/A	$43.72 million	N/A
8/4/2025	Q2 2025	KRYS Krystal Biotech	$1.20	N/A	N/A	N/A	$95.42 million	N/A
5/7/2025	Q3 2025	PAHC Phibro Animal Health	$0.52	$0.63	+$0.11	$0.51	$352.41 million	$347.80 million
5/7/2025	Q1 2025	RYTM Rhythm Pharmaceuticals	-$0.69	-$0.81	-$0.12	-$0.81	$40.43 million	$37.72 million
5/6/2025	Q1 2025	CYTK Cytokinetics	-$1.41	-$1.36	+$0.05	-$1.36	$2.77 million	$1.60 million
5/6/2025	Q1 2025	KRYS Krystal Biotech	$1.38	$1.20	-$0.18	$1.20	$98.66 million	$88.18 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CYTK Cytokinetics	N/A	N/A	N/A	N/A	N/A
KRYS Krystal Biotech	N/A	N/A	N/A	N/A	N/A
PAHC Phibro Animal Health	$0.48	1.57%	N/A	61.54%	N/A
RYTM Rhythm Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Latest PAHC, KRYS, RYTM, and CYTK Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/6/2025	PAHC Phibro Animal Health	quarterly	$0.12	2.52%	6/4/2025	6/4/2025	6/25/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CYTK Cytokinetics	N/A	5.99	5.99
KRYS Krystal Biotech	N/A	9.65	9.27
PAHC Phibro Animal Health	2.67	2.91	1.23
RYTM Rhythm Pharmaceuticals	N/A	3.30	3.13

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CYTK Cytokinetics	N/A
KRYS Krystal Biotech	86.29%
PAHC Phibro Animal Health	99.34%
RYTM Rhythm Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
CYTK Cytokinetics	2.70%
KRYS Krystal Biotech	13.70%
PAHC Phibro Animal Health	50.07%
RYTM Rhythm Pharmaceuticals	6.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CYTK Cytokinetics	250	119.43 million	116.20 million	Optionable
KRYS Krystal Biotech	210	28.90 million	24.94 million	Optionable
PAHC Phibro Animal Health	1,940	40.53 million	20.24 million	Optionable
RYTM Rhythm Pharmaceuticals	140	63.62 million	59.74 million	Optionable

PAHC, KRYS, RYTM, and CYTK Headlines

Recent News About These Companies

Q2 Earnings Estimate for RYTM Issued By Leerink Partnrs

July 16 at 6:25 AM | marketbeat.com

Analysts Set Expectations for RYTM Q4 Earnings

July 15 at 8:23 AM | marketbeat.com

Q2 EPS Estimate for Rhythm Pharmaceuticals Lifted by Analyst

July 15 at 2:12 AM | americanbankingnews.com

Leo Wealth LLC Purchases New Shares in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)

July 14 at 9:16 AM | marketbeat.com

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) CFO Sells $3,389,817.60 in Stock

July 14 at 4:13 AM | americanbankingnews.com

Insider Selling: Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Insider Sells 15,572 Shares of Stock

July 14 at 4:13 AM | americanbankingnews.com

Leerink Partnrs Issues Optimistic Outlook for RYTM Earnings

July 14 at 2:23 AM | marketbeat.com

Alps Advisors Inc. Has $2.45 Million Stock Holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)

July 13, 2025 | marketbeat.com

Bank of America Issues Positive Forecast for Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price

July 13, 2025 | americanbankingnews.com

Wells Fargo & Company Issues Positive Forecast for Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price

July 13, 2025 | americanbankingnews.com

The Goldman Sachs Group Begins Coverage on Rhythm Pharmaceuticals (NASDAQ:RYTM)

July 13, 2025 | americanbankingnews.com

Oppenheimer Forecasts Strong Price Appreciation for Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock

July 13, 2025 | americanbankingnews.com

Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025

July 12, 2025 | globenewswire.com

Rhythm Pharmaceuticals (RYTM) Stock Jumps 36.6%: Will It ... - Nasdaq

July 12, 2025 | nasdaq.com

Insider Selling: Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) CAO Sells 3,817 Shares of Stock

July 12, 2025 | insidertrades.com

Q2 Earnings Forecast for RYTM Issued By Leerink Partnrs

July 12, 2025 | americanbankingnews.com

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) CAO Christopher Paul German Sells 3,817 Shares

July 11, 2025 | marketbeat.com

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Insider Sells $619,828.82 in Stock

July 11, 2025 | marketbeat.com

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Insider Pamela J. Cramer Sells 15,572 Shares

July 11, 2025 | marketbeat.com

Hunter C. Smith Sells 42,120 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Stock

July 11, 2025 | marketbeat.com

Rhythm Pharma gains as mid-stage trial for rare form of obesity succeeds

July 11, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PAHC, KRYS, RYTM, and CYTK Company Descriptions

Cytokinetics NASDAQ:CYTK

$38.68 +0.67 (+1.76%)

Closing price 07/16/2025 04:00 PM Eastern

Extended Trading

$38.49 -0.19 (-0.48%)

As of 04:36 AM Eastern

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Krystal Biotech NASDAQ:KRYS

$150.08 +2.35 (+1.59%)

Closing price 07/16/2025 04:00 PM Eastern

Extended Trading

$149.82 -0.27 (-0.18%)

As of 07:34 AM Eastern

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Phibro Animal Health NASDAQ:PAHC

$30.54 -0.02 (-0.07%)

Closing price 07/16/2025 04:00 PM Eastern

Extended Trading

$31.00 +0.46 (+1.50%)

As of 07:35 AM Eastern

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.

Rhythm Pharmaceuticals NASDAQ:RYTM

$91.44 +2.08 (+2.33%)

Closing price 07/16/2025 04:00 PM Eastern

Extended Trading

$90.71 -0.73 (-0.80%)

As of 07:32 AM Eastern

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time